Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis

Fig. 4

Forest plot of outcomes of IgAN patients treated with corticosteroid plus MMF therapy or corticosteroid plus other immunosuppressive agents. Main analysis and subgroup analysis by therapeutic regimen of remission rate (a), urinary protein reduction (b), serum creatinine doubling rate (c) and side effect rate (d) are provided. CTX, cyclophosphamide; IgAN, immunoglobulin A nephropathy; LEF, leflunomide; MMF, mycophenolate mofetil

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us